DK2293816T3 - Fremgangsmåder til behandling af reumatoid arthritis - Google Patents

Fremgangsmåder til behandling af reumatoid arthritis

Info

Publication number
DK2293816T3
DK2293816T3 DK09759528.4T DK09759528T DK2293816T3 DK 2293816 T3 DK2293816 T3 DK 2293816T3 DK 09759528 T DK09759528 T DK 09759528T DK 2293816 T3 DK2293816 T3 DK 2293816T3
Authority
DK
Denmark
Prior art keywords
treating
methods
reumatoid arthritis
reumatoid
arthritis
Prior art date
Application number
DK09759528.4T
Other languages
Danish (da)
English (en)
Inventor
Alan M Solinger
Alexander Owyang
Original Assignee
Xoma Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd filed Critical Xoma Technology Ltd
Application granted granted Critical
Publication of DK2293816T3 publication Critical patent/DK2293816T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK09759528.4T 2008-06-06 2009-06-05 Fremgangsmåder til behandling af reumatoid arthritis DK2293816T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5971108P 2008-06-06 2008-06-06
US9523208P 2008-09-08 2008-09-08
PCT/US2009/046441 WO2009149370A1 (en) 2008-06-06 2009-06-05 Methods for the treatment of rheumatoid arthritis

Publications (1)

Publication Number Publication Date
DK2293816T3 true DK2293816T3 (da) 2013-02-04

Family

ID=40983388

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09759528.4T DK2293816T3 (da) 2008-06-06 2009-06-05 Fremgangsmåder til behandling af reumatoid arthritis

Country Status (12)

Country Link
US (1) US20110189172A1 (enExample)
EP (1) EP2293816B1 (enExample)
JP (2) JP5607613B2 (enExample)
AU (1) AU2009256072B2 (enExample)
CA (1) CA2727171A1 (enExample)
CY (1) CY1113640T1 (enExample)
DK (1) DK2293816T3 (enExample)
ES (1) ES2398693T3 (enExample)
HR (1) HRP20130042T1 (enExample)
PL (1) PL2293816T3 (enExample)
PT (1) PT2293816E (enExample)
WO (1) WO2009149370A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034014B2 (en) 2007-03-06 2011-10-11 Biomet Biologics, Llc Angiogenesis initation and growth
US20080269762A1 (en) * 2007-04-25 2008-10-30 Biomet Manufacturing Corp. Method and device for repair of cartilage defects
RU2018100129A (ru) 2007-12-20 2019-02-20 Ксома (Сша) Ллс Способы лечения подагры
US8753690B2 (en) * 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
WO2009108890A1 (en) 2008-02-27 2009-09-03 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
JP5844258B2 (ja) 2009-08-27 2016-01-13 バイオメット、バイオロジクス、リミテッド、ライアビリティー、カンパニーＢｉｏｍｅｔ Ｂｉｏｌｏｇｉｃｓ， Ｌｌｃ インターロイキン−１受容体アンタゴニストの生産のための植込み型装置
US20110052561A1 (en) * 2009-08-27 2011-03-03 Biomet Biologics,LLC Osteolysis treatment
AU2011296356B2 (en) 2010-09-03 2015-07-09 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
WO2012034039A2 (en) 2010-09-10 2012-03-15 Apexigen, Inc. Anti-il-1 beta antibodies and methods of use
US9011846B2 (en) 2011-05-02 2015-04-21 Biomet Biologics, Llc Thrombin isolated from blood and blood fractions
CN104203979B (zh) * 2012-03-19 2017-08-08 法国国家健康医学研究院 用于动脉瘤的治疗或预防的方法和药物组合物
MX374817B (es) * 2012-11-05 2025-03-06 Delenex Therapeutics Ag Miembros de union para il-1 beta.
ES2895848T3 (es) 2012-12-17 2022-02-22 Cell Medica Inc Anticuerpos contra IL-1 beta
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
WO2015081253A1 (en) 2013-11-26 2015-06-04 Biomet Biologics, Llc Methods of mediating macrophage phenotypes
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
WO2016075035A1 (en) 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Anti-ang2 antibodies and methods of use
JP2017537896A (ja) 2014-11-10 2017-12-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二重特異性抗体及び眼科に使用する方法
US9763800B2 (en) 2015-03-18 2017-09-19 Biomet C. V. Implant configured for hammertoe and small bone fixation
CN113444177A (zh) * 2020-03-27 2021-09-28 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
CN115281149A (zh) * 2021-05-12 2022-11-04 四川大学华西医院 一种临床前类风湿关节炎(Pre-RA)小鼠模型

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0569687B1 (en) * 1984-05-18 2002-08-21 New England Medical Center Hospitals, Inc. Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
US4762914A (en) * 1984-05-18 1988-08-09 Auron Philip E Truncated protein of interleukin-1
US5077219A (en) * 1984-05-18 1991-12-31 New England Medical Center Hospitals Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
US5484887A (en) * 1984-06-19 1996-01-16 Immunex Corporation Homogeneous interleukin 1
US5122459A (en) * 1984-12-31 1992-06-16 Immunex Corporation Gene encoding biologically active human interleukin 1
US4772685A (en) * 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
US5474899A (en) * 1987-05-13 1995-12-12 Cistron Biotechnology, Inc. Selective immunoassay for IL-1 β
DE68925935T2 (de) * 1988-10-01 1996-08-14 Otsuka Pharma Co Ltd Antikörper gegen Interleukin-1-beta
ATE165114T1 (de) * 1989-02-27 1998-05-15 New England Medical Center Inc Il-1, dessen biologische aktivität inhibiert ist
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
PT1024191E (pt) * 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
WO1993011794A1 (en) * 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
WO1994000470A1 (en) * 1992-06-30 1994-01-06 The Wistar Institute Of Anatomy And Biology DEVELOPMENTAL EMBRYONIC MOUSE cDNA LIBRARIES
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5817476A (en) * 1995-06-07 1998-10-06 Genetics Institute, Inc. Polynucleotides encoding interleukin-1 receptor intracellular ligand proteins
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
EP1282435A2 (en) * 2000-05-12 2003-02-12 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US20030166069A1 (en) * 2000-11-28 2003-09-04 Amgen, Inc. Interleukin-1 receptor antagonist-like molecules and uses thereof
US6727234B2 (en) * 2001-04-03 2004-04-27 University Of Iowa Research Foundation Isoprenoid analog compounds and methods of making and use thereof
US20050075488A1 (en) * 2001-07-26 2005-04-07 Bright Stuart Willis Interleukin-1 beta antibodies
US20050152850A1 (en) * 2004-01-09 2005-07-14 Engebretson Steven P. Methods and compositions for facilitating metabolic control
US7732478B2 (en) * 2004-01-09 2010-06-08 The Trustees Of Columbia University In The City Of New York Methods for facilitating metabolic control
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
ES2335232T3 (es) * 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
CA2963828A1 (en) * 2005-10-26 2007-05-03 Novartis Ag Novel use of il-1beta compounds
WO2008077145A2 (en) * 2006-12-20 2008-06-26 Xoma Technology Ltd. Treatment of il-1-beta related diseases
RU2018100129A (ru) * 2007-12-20 2019-02-20 Ксома (Сша) Ллс Способы лечения подагры

Also Published As

Publication number Publication date
EP2293816A1 (en) 2011-03-16
PT2293816E (pt) 2013-02-13
HRP20130042T1 (hr) 2013-03-31
AU2009256072A1 (en) 2009-12-10
JP2015007098A (ja) 2015-01-15
ES2398693T3 (es) 2013-03-21
PL2293816T3 (pl) 2013-04-30
US20110189172A1 (en) 2011-08-04
CY1113640T1 (el) 2016-06-22
WO2009149370A1 (en) 2009-12-10
JP2011522832A (ja) 2011-08-04
JP5607613B2 (ja) 2014-10-15
AU2009256072B2 (en) 2015-05-28
JP5809338B2 (ja) 2015-11-10
EP2293816B1 (en) 2012-11-07
CA2727171A1 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
DK2212070T3 (da) Fremgangsmåde til behandling af træ
DK3412687T3 (da) Fremgangsmåder til behandling af dlbcl
DK3757126T3 (da) Fremgangsmåder til behandling af psoriasisgigt ved hjælp af il-17-antagonister
DK2325648T3 (da) Fremgangsmåde til detektering af cancer
DK3289876T3 (da) Forbindelser til behandling af cancer
DK2310034T3 (da) Peptider til behandling af beta-amyloidose
DK2350096T3 (da) Fremgangsmåder til behandling af hepatisk encephalopati
DK3329775T3 (da) Fremgangsmåder til syntese af diarylthiohydantoin- og diarylhydantoinforbindelser
BRPI0919116A2 (pt) método
DK2563739T3 (da) Fremgangsmåde til fremstilling af mursten ved hjælp af enzymproducerende bakterier
DK2215047T3 (da) Fremgangsmåde til behandling af vitamin b12-mangel
HUE037539T2 (hu) Többvivõs engedélyezési módszer
DK2350116T3 (da) Behandling af biofilm
DK2111555T3 (da) Diagnosticering af præeklampsi
DK2311970T3 (da) Fremgangsmåde til fremstillingen af bioprodukter
DK2452189T3 (da) Fremgangsmåde til identifikation af forbindelser til behandling af cancer
DK2358714T3 (da) Alkylcyclohexylethere af dihydrotetraazabenzoazulener
DK2313489T3 (da) Fremstillingsmetode
DK3106873T3 (da) Fremgangsmåde til detektering af cancer
DK2382232T3 (da) Fremgangsmåde til fremstilling af bivalirudin
DK2342346T3 (da) Thermotoga til behandling af biomasse
DK3214083T3 (da) Fremgangsmåde til fremstilling af quinolonforbindelser
DK2346661T3 (da) Dannelsesfremgangsmåder
DK2554174T3 (da) Fremgangsmåde til behandling af sygdomme
DK2506840T3 (da) Anvendelser af hæmmere af hypoksi-fremkaldende faktorer